Jeff Lange

Company: Virogin Biotech

Job title: Executive Vice President, Business Development

Seminars:

Oncolytic Virotherapy: Turning Anti-Viral Immunity to Anti-Cancer 1:30 pm

Reviewing requirements for a good oncolytic virus including, potent tumor specific lytic activity to release sufficient amount of tumor antigens, strong regulation on tumor microenvironment to convert an anti-viral immunity to anti-tumor Reviewing of the Virogin Biotech oncolytic virus pipeline which is more potent in causing tumor lysis while remaining highly tumor specific [Transcription and…Read more

day: Day One